Caliper Life Sciences enters into new agreement

Caliper Life Sciences has announced that it has entered into a new cross-licensing agreement with AntiCancer.

Following the move, all outstanding patent litigation between the two firms will come to an end and Caliper has the rights to sublicense AntiCancer’s fluorescent protein optical imaging patents.

Meanwhile, AntiCaner will have the right to sublicense Caliper’s optical imaging patents to third-parties.

Commenting on the agreement, Kevin Hrusovsky, president and chief executive officer of Caliper, said that the move is a "major step forward" for the vivo molecular imaging sector.

"In addition to our unique position in bioluminescent and fluorescent conjugate imaging, the cross-licensing arrangement enables Caliper to provide our existing and prospective license customers with a broader suite of intellectual property rights for optical imaging with fluorescent proteins," he explained.

In related news, Caliper recently revealed its fourth quarter and full-year financial results for 2007.

The firm stated that its fourth quarter revenues increased by 16 per cent on the same period in 2006.